Jeong Eun Ju, Liu Xing, Jia Xiaobin, Chen Jun, Hu Ming
Department of Pharmacological and Pharmaceutical Sciences, 1441 Moursund St., College of Pharmacy, University of Houston, TX 77030, USA.
Curr Drug Metab. 2005 Oct;6(5):455-68. doi: 10.2174/138920005774330657.
Abstract: Conjugating enzymes are traditionally recognized as one of the major biological barriers to the entry of xenobiotics/drugs into systemic circulation and represent one of the main pathways for their elimination. Similar to drugs that undergo extensive phase I metabolism, drugs that undergo extensive conjugation have poor bioavailability and are more prone to metabolism-based drug interactions. Previously, enterohepatic recycling is used to explain why certain xenobiotics have half-lives that are much longer than expected from intravenous injection studies. In addition, changes in expression levels of metabolic enzymes due to chemical induction or suppression are often recognized as the source of drug interaction or toxicity of pollutants and carcinogens. These traditional approaches, whereas yielding highly valuable information, fail to recognize the fact that many conjugates (especially hydrophilic ones) cannot permeate the cell membrane. In the present review, we will focus on the coupling process that involves both conjugating enzymes and efflux transporters. We will briefly review conjugating enzymes capable of producing highly hydrophilic metabolic products. The other focus of this review is on various transporters capable of moving negatively charged hydrophilic conjugates across the cellular membrane. Evidence will support the hypothesis that efficient coupling of the conjugating enzymes and efflux transporters enables enterohepatic recycling and enteric recycling processes. Termed as a "revolving door" theory, the hypothesis focuses on the role played by efflux transporter capable of modulating the cellular excretion of hydrophilic metabolites. Coupling process in intestine, liver and kidney will be discussed with an emphasis on the intestinal coupling process, since we have just begun to understand it. Biological consequence and new insights into how coupling process can impact bioavailability of xenobiotics, biological functions of drugs and carcinogens, and drug interactions will be discussed.
结合酶传统上被认为是外源性物质/药物进入体循环的主要生物屏障之一,也是它们消除的主要途径之一。与经历广泛I相代谢的药物类似,经历广泛结合的药物生物利用度差,更容易发生基于代谢的药物相互作用。以前,肝肠循环被用来解释为什么某些外源性物质的半衰期比静脉注射研究预期的要长得多。此外,由于化学诱导或抑制导致的代谢酶表达水平变化,常被认为是药物相互作用或污染物及致癌物毒性的来源。这些传统方法虽然产生了非常有价值的信息,但未能认识到许多结合物(尤其是亲水性结合物)不能穿透细胞膜这一事实。在本综述中,我们将重点关注涉及结合酶和外排转运体的偶联过程。我们将简要回顾能够产生高度亲水性代谢产物的结合酶。本综述的另一个重点是各种能够将带负电荷的亲水性结合物转运穿过细胞膜的转运体。有证据支持这样的假设,即结合酶和外排转运体的有效偶联能够实现肝肠循环和肠循环过程。这个假设被称为“旋转门”理论,它关注能够调节亲水性代谢产物细胞排泄的外排转运体所起的作用。将讨论肠道、肝脏和肾脏中的偶联过程,重点是肠道偶联过程,因为我们才刚刚开始了解它。还将讨论偶联过程如何影响外源性物质的生物利用度、药物和致癌物的生物学功能以及药物相互作用的生物学后果和新见解。